Randomized controlled trials establish strict inclusion and exclusion criteria in an effort to optimize the cohort of trial participants.
Dan Riskin
Advertisement
Articles by Dan Riskin
The FDA has been working to enable greater adoption of RWE in clinical and regulatory decisions, as mandated by the 21st Century Cures Act.
Advertisement
Latest Updated Articles
- Real-World Evidence Studies can Enhance Diversity and Equity in Clinical Research
Published: October 23rd 2020 | Updated:
- How to Transition RWE Studies from Non-Clinical to Regulatory-Grade
Published: January 10th 2019 | Updated:
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
